ALVESCO Drug Patent Profile

When do Alvesco patents expire, and when can generic versions of Alvesco launch?

Alvesco is a drug marketed by Azurity and is included in one NDA. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.

DrugPatentWatch^® Generic Entry Outlook for Alvesco

Alvesco was eligible for patent challenges on October 20, 2010.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 1, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ALVESCO

International Patents:	14
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	11
Drug Prices:	Drug price information for ALVESCO
What excipients (inactive ingredients) are in ALVESCO?	ALVESCO excipients list
DailyMed Link:	ALVESCO at DailyMed

See drug prices for ALVESCO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ALVESCO

Constraining patent/regulatory exclusivity:

8,371,292

NDA:

021658

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALVESCO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Pittsburgh	PHASE1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	PHASE1
Children's Mercy Hospital Kansas City	PHASE1

See all ALVESCO clinical trials

US Patents and Regulatory Information for ALVESCO

ALVESCO is protected by one US patents.

This potential generic entry date is based on patent 8,371,292.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-002	Jan 10, 2008		RX	Yes	Yes	8,371,292
Azurity	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008		RX	Yes	Yes	8,371,292

Expired US Patents for ALVESCO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-002	Jan 10, 2008	6,006,745
Azurity	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	6,006,745
Azurity	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-002	Jan 10, 2008	5,482,934

EU/EMA Drug Approvals for ALVESCO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim Vetmedica GmbH	Aservo EquiHaler	ciclesonide	EMEA/V/C/004991For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction – (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)).	Authorised	no	no	no	2020-01-28

International Patents for ALVESCO

See the table below for patents covering ALVESCO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	402930
Austria	A176991
Australia	649472

Supplementary Protection Certificates for ALVESCO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0983058	CA 2005 00036	Denmark
0983058	PA2005006	Lithuania		PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321
0983058	PA2005006,C0983058	Lithuania		PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321

Last updated: July 26, 2026

Alvesco (ciclesonide) market dynamics, revenue trajectory, and competitive outlook (US and major markets)

Executive summary: Alvesco (ciclesonide) generates revenue primarily in the US inhaled corticosteroid (ICS) market for asthma and in COPD-related off-label use. Financial trajectory is driven by (1) patent and exclusivity-driven generic pressure cycles, (2) payer formulary position versus competing ICS inhalers, and (3) platform economics tied to aerosol device performance (spray plume and lung delivery) and contracting. The brand’s competitive set is led by other ICS/device combinations including fluticasone/salmeterol and budesonide-formoterol products, plus generic and branded monotherapy ICS inhalers that compress wholesale and net-to-gross pricing. Key watch items for future market dynamics are generic penetration timing for ciclesonide inhaler presentations, payer switching incentives within ICS subclasses, and any new-label or device reformulation strategy by the brand holder.

---

How has Alvesco’s revenue performed and what drives its financial trajectory?

Quick answer: Alvesco’s financial trajectory tracks the US ICS market cycle: brand pricing power declines over time as generics and competing branded combination therapies gain formulary share, while net sales are defended through contracting, step-therapy position, and substitution resistance related to device handling and clinical fit.

US market drivers: formulary position, net pricing, and utilization

Alvesco’s revenue performance is shaped by:

• Net price pressure from ICS genericization: ICS inhalers have sustained generic uptake in the US, which usually forces brand discounts and access restrictions.
• Payer benefit design and step edits: Many plans steer patients toward lower-cost ICS options first, reserving Alvesco for inadequate response or specific patient-device compatibility.
• Device differentiation and adherence economics: Alvesco’s aerosol delivery behavior and patient handling influence continuation rates, which affects pharmacy claims and contracting leverage.

What financial indicators usually move for Alvesco

Revenue and profitability for an ICS inhaler brand typically respond to:

• Wholesale-to-net compression (rebates and discounts tied to formulary placement)
• Channel mix (commercial vs managed care vs government)
• Seasonality tied to asthma exacerbation cycles

Revenue trajectory pattern commonly seen in ICS brands

• Early period: strong adoption within ICS-naïve and guideline-based prescribing.
• Mid period: share loss to generics and combination inhalers.
• Late period: marginal growth becomes harder; revenue stabilizes via contracting and niche patient retention, with decline risk when additional low-cost alternatives become preferred.

---

What market share and competitive dynamics affect Alvesco’s sales?

Quick answer: Alvesco competes in a crowded asthma controller segment where formulary rules and combination products shift utilization. Market dynamics are dominated by plan formularies, step-therapy requirements, and the relative cost-effectiveness of comparable-dose ICS options delivered via inhalers.

Primary competitive set

Alvesco is most often evaluated against:

• ICS monotherapies: budesonide, fluticasone, mometasone (often generic).
• ICS/LABA combinations: budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol (brand or generic depending on molecule).
• Nonsteroid controller options: leukotriene receptor antagonists and combination controller strategies (typically secondary to ICS in payer models).

Why payers shift patients between ICS inhalers

Payers use:

• Preferred product lists inside each inhaler class
• Copay tiers that favor preferred generics or lower-cost brands
• Clinical criteria to justify non-preferred use

How device and patient selection affect dynamics

ICS inhaler switching can be constrained by:

• Patient technique and perceived ease of use
• Sensitivity to spray characteristics and plume perception
• Clinical response patterns and tolerability

---

When do generics and exclusivity events change Alvesco market access?

Quick answer: Market access risk rises around generic launch windows for ciclesonide inhaler presentations and any expiration of formulation, device, or method-of-use protections. After entry, net sales typically fall first through access restrictions and then through volume migration to generics or preferred substitutes.

Exclusivity vs patent-driven entry

ICS inhalers often face:

• Patent expiration on composition, formulation, and delivery device improvements
• Paragraph IV litigation risk when generics file early
• Regulatory exclusivity (where applicable to specific NDAs or supplements)

What to monitor for Alvesco

• Orange Book listing changes tied to launch-ready ANDAs
• Court outcomes on patent validity or non-infringement
• Settlement agreements that set launch dates or design-around conditions

---

What patents protect Alvesco and how do they influence market dynamics?

Quick answer: The strength and remaining life of Alvesco’s patent estate determines how long brand exclusivity holds and whether generic challengers face multiple blocking patents. In inhalers, patent scope commonly includes formulation/process claims and device-related claims that can slow generic design-around.

Patent estate categories that matter to launch timing

• Composition and polymorph/formulation claims (particle properties, stability)
• Device delivery and aerosol performance claims (spray, valve/nozzle, plume)
• Method-of-use claims (asthma dosing regimens, patient subsets)

How patent depth translates to commercial outcomes

• Multiple blocking patents increase the likelihood of longer stays of generic launch or delayed entry.
• Narrow claims can reduce settlement leverage, increasing the chance of earlier launch with a design-around.

---

What generic entry risks exist for Alvesco and what happens after launch?

Quick answer: Generic entry risks are highest when the last enforceable patents covering the specific inhaler presentation expire or fail in litigation. Post-launch dynamics usually show rapid share loss, followed by price competition that compresses net sales.

Typical post-launch sequence in inhaled controller markets

1. Initial launch with limited formulary access
2. Formulary repositioning after evidence of bioequivalence and budget impact
3. Copay tier changes that accelerate switching
4. Subsequent erosion as additional generics enter or as PBMs broaden preferred status

Commercial mitigation strategies

Brand holders usually respond with:

• Contracting changes to keep preferred status
• Patient-assistance programs
• Support programs for prescribers to reduce forced switching

---

What is the Orange Book status of Alvesco and how does it map to launch scenarios?

Quick answer: Orange Book status is a practical proxy for how many patents can block an ANDA. The controlling issue is whether there are unexpired patents listed for the relevant strength and dosage form, and which patents have active litigation.

How to translate Orange Book listings into a launch timeline

• Identify the expiration dates for the listed patents tied to the NDA and strengths.
• Identify which listed patents have active Paragraph IV litigation.
• Map generic filing dates and court outcomes to expected launch windows.

---

What formulations and delivery devices are protected for Alvesco?

Quick answer: For ICS inhalers, protected “product” typically includes the specific formulation strength and the integrated aerosol delivery system. Any generic must reproduce the labeled strength and demonstrate equivalence for the specific dosage form to be substitutable.

Formulation and device elements that drive equivalence and switching

• Excipients and suspension stability
• Delivered dose per actuation and plume characteristics
• Inhaler mechanics that influence respirable fraction

---

How does Alvesco compare with other inhaled corticosteroids on payer and clinical positioning?

Quick answer: Alvesco competes as an ICS monotherapy controller and is usually positioned against other ICS options as a step-up controller when preferred products fail or when patient-device fit matters. Combination products compete for the same asthma-controller budget, pulling volume away from monotherapy.

Comparison dimensions that influence prescribing

• Expected steroid exposure and clinical response
• Inhaler usability and adherence outcomes
• Prior authorization burden and formulary criteria

Market impact of combination therapies

ICS/LABA combinations often win:

• Patients requiring symptom control beyond monotherapy
• Prescribers wanting single-inhaler convenience
• Payers seeking simplified step regimens

---

Which companies are likely competing with Alvesco and how do they win access?

Quick answer: Competition comes from generic manufacturers of ICS inhalers and branded competitors in ICS/LABA. Access wins are driven by lower acquisition cost, preferred status on PBM lists, and rebate contracting strength.

How competing players typically approach contracting

• PBM negotiations emphasizing net cost targets
• Formulary placements tied to utilization commitments
• Co-pay strategies to preserve patient continuity for preferred brands

---

What patent litigation and settlements have shaped Alvesco’s timeline?

Quick answer: In inhaler portfolios, litigation typically determines whether generic challengers launch on patent expiry or at later negotiated dates. The commercial impact is reflected in whether generic entry causes immediate net sales decline or a delayed erosion after settlements.

What litigation outcomes matter most commercially

• Injunctions that block launch until court resolution
• Validity rulings that eliminate blocking patents
• Settlement terms that set design-around requirements or delayed effective launch dates

---

What is Alvesco’s FDA status and how does it affect market adoption?

Quick answer: As an approved inhaled corticosteroid controller, Alvesco adoption depends on labeled asthma indications, dosing convenience, and payer criteria for controller therapy coverage.

Regulatory factors that affect commercial dynamics

• Labeling that supports insurer criteria
• Any supplement-related changes that affect dosing or device compatibility
• Substitution rules linked to therapeutic equivalence and inhaler classification

---

Commercial outlook: what scenarios could change Alvesco market share next?

Quick answer: The next market-share inflection points are (1) generic launch events for ciclesonide inhalers if they occur, (2) payer preference shifts within ICS and toward combination controller options, and (3) new device or formulation improvements that reset differentiation.

High-probability scenarios

• Gradual share erosion if generics or preferred competitors expand across PBMs.
• Stabilization in niche populations where device fit and adherence are strong.
• Accelerated decline if formulary tiers lower Alvesco or if multiple generics appear concurrently.

Low-probability but high-impact scenarios

• Reformulation/device update that creates a new patent-protected presentation.
• New clinical or guideline positioning that increases controller monotherapy relevance.

---

Key Takeaways

• Alvesco’s revenue trajectory is governed by net price pressure, formulary position, and switching dynamics versus generic ICS and combination therapies.
• Market share is vulnerable to generic entry waves for ciclesonide inhaler presentations and to PBM preference shifts within the ICS controller class.
• Patent estate depth and Orange Book blockages determine whether generic entry triggers immediate sales erosion or a delayed, negotiated decline pattern.
• The commercial future turns on contracting outcomes and whether Alvesco retains a defendable niche in patient populations that resist switching due to device handling and demonstrated control.

---

FAQs

1. What factors most affect net sales for ciclesonide inhalers like Alvesco?
   Net-to-gross compression from PBM rebates, formulary tier placement, and switching rates driven by payer step edits.

2. How do ICS/LABA combination products change the competitive landscape for Alvesco?
   They take share from ICS monotherapy among patients who need symptom control beyond what payers consider achievable with monotherapy.

3. What determines whether a generic ciclesonide inhaler can launch successfully?
   Whether ANDA approvals are blocked by unexpired Orange Book patents and whether Paragraph IV litigation outcomes and settlements permit launch.

4. Do device differences influence uptake of inhaled corticosteroid generics?
   Yes. Patient technique and inhaler handling can limit forced substitution and slow migration in some segments.

5. How do patent expirations typically show up in sales charts for inhaled brands?
   Revenue often declines first through access restrictions and later through volume switching after generics gain preferred formulary status.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA. Drug Approval Reports and labeling for Alvesco (ciclesonide). (Accessed 2026).

DrugChatter Q&A for ALVESCO

Why is alvesco so expensive?
Alvesco inhaler goodrx price?
Alvesco cost without insurance?
Alvesco 80 mcg inhaler price?